Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Overview

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Inclusion criteria: diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT

Conditions

Eligibility

Locations (1)

Outcomes

Central Contacts